bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has been named a 2014 Technology Pioneer, a prestigious award from the World Economic Forum honoring the world’s most innovative technology start-ups. bluebird bio was selected for its efforts in developing gene therapies for severe genetic and orphan diseases.
bluebird bio’s gene therapy platform holds the promise of delivering a one-time treatment for a wide variety of diseases. The company’s initial focus is on genetic diseases caused by a known mutation in a single gene. Through the application of gene therapy, bluebird is developing product candidates designed to insert a functional gene into a patient, potentially correcting their underlying disease. In addition to genetic diseases, bluebird and its partners are also utilizing this technology to develop product candidates intended to treat various cancers, by targeting a patient’s own immune system to seek out and kill cancer cells in the body, offering a new approach to cancer treatment.
“bluebird bio is seeking to bring transformative gene therapies to patients” stated Nick Leschly, Chief bluebird. “We consider recognition by the World Economic Forum to be a rewarding validation of the team’s hard work and dedication to developing these innovative therapies for patients around the world.”
The World Economic Forum class of 2014 Technology Pioneers includes 36 innovative technology start-ups chosen for their potential to transform the future of business and society. Each year the World Economic Forum chooses its Technology Pioneers from hundreds of applicants that are vetted by a distinguished selection committee of technology and innovation experts.The head of the New Champions at the World Economic Forum, David Aikman, noted: “The diversity of the innovative thinking and possible solutions they offer are why leaders from all sectors of society are interested in interacting with the Technology Pioneers.” bluebird bio and the 2014 Technology Pioneers will be honored at the Forum’s Annual Meeting of the New Champions 2013 in Dalian, People’s Republic of China, from September 11-13, 2013.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV